1. Latest News
  2. Submit Press Release

Kindred Bio Announces Filing of an Investigational New Animal Drug Application

KIND-001, a potent and specific inhibitor of inflammatory cytokines, is expected to be a major new therapy for diseases in dogs.

Dec. 31, 2012 - PRLog -- SAN FRANCISCO, California. - Kindred Biosciences, Inc. (Kindred Bio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-001. KIND-001 is a potent inhibitor and downregulator of multiple key molecules involved in inflammatory and immune diseases, including tumor necrosis factor. It is expected be a major step forward in the treatment of several important inflammatory, immune, and other diseases in dogs.

“We are delighted to file our first INAD. KIND-001 is a promising molecule, supported by extraordinarily strong scientific data. We look forward to advancing it for the benefit of numerous dogs with great unmet medical need.” stated Richard Chin, Chief Executive Officer of Kindred Bio. “The rapid filing of this INAD is a testament to the dedication and quality of our world-class team. The filing meets a major corporate milestone and demonstrates Kindred Bio’s commitment to operational and executional excellence.”

About Kindred Bio

“Best Medicines for Our Best Friends”

Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Kindred Bio’s proprietary Canibody-FEMTO™, Felibody-FEMTO™, and Equibody-FEMTO™ antibody technologies have the potential to revolutionize the treatment of companion animals.

Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals with experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.

Forward Looking Statements

The inclusion of forward-looking statements in this news release should not be regarded as a representation that any of the company's plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement.  These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.

Trademark Acknowledgements

Lucentis® is a registered trademark of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.

Denise Bevers
Kindred Bio
(650) 701-7908

--- End ---

Click to Share

Contact Email:
***@kindredbio.com Email Verified
Source:Kindred Biosciences, Inc.
Location:San Francisco - California - United States
Industry:Veterinary, Biotechnology
Tags:Veterinary, Companion Animals, Pets, Pharmaceutical, Biotechnology
Last Updated:Jan 08, 2013
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

Like PRLog?
Click to Share